Lonza Significantly Expands ADC Manufacturing Capacity in Switzerland to Meet Surging Demand
Lonza, a leading CDMO (Contract Development and Manufacturing Organization), has announced a substantial expansion of its manufacturing capacity to address the rapidly growing demand in the antibody-drug conjugate (ADC) market. The company is broadening its partnership with a major US pharmaceutical firm to enhance support across the entire ADC manufacturing process. This strategic investment is aimed at accelerating the development and commercialization of ADC therapeutics.
New Facilities for Payload-Linker Manufacturing and HPAPI/ADC Production
The core of Lonza’s capacity enhancement will take place at its key R&D and manufacturing site in Visp, Switzerland. Specifically, the company will increase its capabilities for manufacturing payload-linkers, which are critical components of ADCs. Payload-linkers connect the antibody to the cytotoxic payload and significantly influence the ADC’s stability, specificity, and therapeutic efficacy.
Furthermore, Lonza plans to establish a new commercial-scale facility for the production of high-potency active pharmaceutical ingredients (HPAPI) and the final ADC drug substance. HPAPIs, due to their potent pharmacological effects, require extremely stringent containment and specialized handling. The new facility will be designed to meet these complex manufacturing requirements, incorporating advanced technology and safety management systems.
Background and Industry Impact
ADCs have garnered significant attention as “magic bullets” capable of selectively delivering drugs to specific cancer cells, leading to a rapid market expansion driven by an increasing number of approved drugs and a growing pipeline. However, their complex manufacturing processes—including antibody production, payload synthesis, linker conjugation, and drug-conjugation—demand high technical expertise and specialized facilities, often creating manufacturing bottlenecks. The capacity expansion by CDMOs like Lonza is crucial for the entire industry, enabling pharmaceutical companies to bring ADC therapeutics to market more quickly and efficiently.
This upgrade at the Visp site is expected to be operational by 2028, further strengthening Lonza’s ability to support ADC programs from clinical stages through commercial production. As a result, client companies will be able to reduce the time it takes to deliver innovative ADC therapies to patients.
Future Outlook
Lonza’s strategic expansion of manufacturing capacity underscores the sustained growth of the ADC market and the critical importance of specialized CDMOs in complex biopharmaceutical manufacturing. This investment is essential for the company to maintain and enhance its position as a key player in the ADC supply chain and to support the development of next-generation cancer treatments. Moving forward, continuous technological innovation and improvements in manufacturing efficiency are expected to bring more safe and effective ADCs to market, contributing to improved outcomes for cancer patients.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments